Harrow executes five-year supply, development agreement for Triesence

Harrow (HROW) announced the execution of a five-year strategic supply and development agreement for Triesence 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. The SSD agreement is with the current contract manufacturing organization producing Triesence, ensuring continuity in quality and leveraging more than 15 years of experience with the Triesence manufacturing process. Harrow also announced that it has begun developing a next-generation version of Triesence and plans to submit a new drug application to the FDA before the end of 2027.